Jenks, Jeffrey DHoenigl, Martin2023-08-012023-08-012020-101473-71591744-8352https://hdl.handle.net/10161/28620<h4>Introduction</h4>The spectrum of disease caused by <i>Aspergillus</i> spp. is dependent on the immune system of the host, with invasive aspergillosis (IA) its most severe manifestation. Early and reliable diagnosis of <i>Aspergillus</i> disease is important to decrease associated morbidity and mortality from IA.<h4>Areas covered</h4>The following review searched Pub Med for literature published since 2007 and will give an update on the current point-of-care diagnostic strategies for the diagnosis of IA, discuss needed areas of improvement for these tests, and future directions.<h4>Expert opinion</h4>Several new diagnostic tests for IA - including point-of-care tests - are now available to complement conventional galactomannan (GM) testing. In particular, the <i>Aspergillus</i>-specific Lateral Flow Device (LFD) test and the sōna <i>Aspergillus</i> GM Lateral Flow Assay (LFA) are promising for the diagnosis of IA in patients with hematologic malignancy, although further evaluation in the non-hematology setting is needed. In addition, a true point-of-care test, particularly for easily obtained specimens like serum or urine that can be done at the bedside or in the Clinic in a matter of minutes is needed, such as the lateral flow dipstick test, which is under current evaluation. Lastly, improved diagnostic algorithms to diagnose IA in non-neutropenic patients is needed.HumansAspergillosisDisease SusceptibilitySensitivity and SpecificityReproducibility of ResultsAlgorithmsDisease ManagementClinical Decision-MakingPoint-of-Care TestingInvasive Fungal InfectionsJournal article2023-08-01